Results 141 to 148 of about 3,972 (148)

Larotrectinib for the treatment of TRK fusion solid tumors

Expert Review of Anticancer Therapy, 2019
Douglas S Hawkins, Theodore W Laetsch
exaly  

TRK Inhibitors: Clinical Development of Larotrectinib

Current Oncology Reports, 2019
Darren Sigal, Munveer S Bhangoo
exaly  

NTRK-1 fusion in endocervical fibroblastic malignant peripheral nerve sheath tumor marking eligibility for larotrectinib therapy: A case report

Gynecologic Oncology Reports, 2019
Ali Wells, Damon R. Reed
exaly  

Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer

European Journal of Cancer
Domnita-Ileana Burcoveanu
exaly  

Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

ESMO Open
Alexander Drilon, Daniel Orbach, Theodore W Laetsch   +2 more
exaly  

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

Oncologist
Alexander Drilon, Jessica R Bauman, David Hong   +2 more
exaly  

Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis

Clinics
Meihua Wang, Yu Gai
exaly  

Cost-effectiveness analysis of larotrectinib vs standard of care for treatment of metastatic NTRK fusion colorectal cancer

Expert Review of Pharmacoeconomics and Outcomes Research
exaly